Patents Examined by Robert S. Landsman
  • Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
    Patent number: 11512141
    Abstract: Provided herein are anti-FGL2 monoclonal antibodies. Further provided herein are methods to reverse suppressive immune mechanisms, such as for the treatment of cancer or infectious diseases.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: November 29, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Shulin Li, Jun Yan, Jiemiao Hu, Xueqing Xia, Qingnan Zhao
  • Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels
    Patent number: 11498970
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: November 15, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof
    Patent number: 11492403
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 8, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins
    Patent number: 11479613
    Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: October 25, 2022
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Matteo Righi, James Sillibourne, Shimobi Onuoha, Simon Thomas
  • Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors
    Patent number: 11479614
    Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: October 25, 2022
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Matteo Righi, James Sillibourne, Shimobi Onuoha, Simon Thomas
  • Method of treating epithelial growth factor receptor (EGFR) T790M-positive non-small cell lung cancer by administering a combination of a VEGFR-2 antibody and osimertinib
    Patent number: 11471457
    Abstract: The present invention relates to a combination of anti-human VEGFR-2 antibodies and human EGFR tyrosine kinase inhibitors for the treatment of T790M-positive EGFR-mutant non-small cell lung cancer.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 18, 2022
    Assignees: Eli Lilly and Company, Medimmune Limited
    Inventors: Bo Hua Chao, Sang Min Lee
  • Adeno-associated virus antibodies, fragments thereof and encoding polynucleotides
    Patent number: 11472866
    Abstract: The present disclosure relates to an isolated anti-AAV (adeno-associated virus) antibody or an antigen-binding fragment thereof capable of specifically binding an epitope of AAVrh74 capsid protein and uses thereof.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: October 18, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Sohrab Khan, Danielle Griffin, Louise Rodino-Klapac
  • Methods of identifying a moldulator of otopetrin-mediated proton translocation activity
    Patent number: 11467168
    Abstract: Presented herein are compositions and devices comprising otopetrin polypeptides and uses thereof for identifying modulators of proton translocation activity through an otopetrin polypeptide, or functional portion thereof.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: October 11, 2022
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Emily Liman, Yu-Hsiang Tu
  • Anti-human nicotinamide phosphoribosyltransferase (NAMPT) antibodies
    Patent number: 11466099
    Abstract: Anti-nicotinamide phosphoribosyltransferase (NAMPT) antibodies, or antigen binding fragments thereof, are described, as well as methods for treating a subject having a (NAMPT)-associated local and/or systemic inflammatory disorder.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: October 11, 2022
    Assignee: Aqualung Therapeutics Corp.
    Inventors: Joe G. N. Garcia, Darragh Maccann
  • Monoclonal antibodies that bind human CD161
    Patent number: 11459389
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: October 4, 2022
    Assignees: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Karl Dane Wittrup, Kai Wucherpfennig, Byong Ha Kang, Nathan D. Mathewson
  • Fusion proteins (Seldegs) for selectively depleting antigen-specific antibodies and methods of use thereof
    Patent number: 11459396
    Abstract: The present disclosure includes a fusion protein, called a “Seldeg”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: October 4, 2022
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Elizabeth Sally Ward Ober, Venkata Siva Charan Devanaboyina, Raimund Johannes Ober
  • Methods of treating a subject suffering from rheumatoid arthritis based in part on a trained machine learning classifier
    Patent number: 11456056
    Abstract: Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising a step of: administering an anti-TNF therapy to subjects who have been determined to be responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: September 27, 2022
    Assignee: SCIPHER MEDICINE CORPORATION
    Inventors: Susan Ghiassian, Theodore R. Mellors, Marc Santolini, Asher Ameli, Nancy Schoenbrunner, Viatcheslav R. Akmaev, Keith J. Johnson
  • Host cells for use in an inducible coexpression system
    Patent number: 11447781
    Abstract: The present invention provides host cells for use in an inducible coexpression system that is capable of controlled induction of expression of each gene product.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: September 20, 2022
    Assignee: ABSCI LLC
    Inventors: Sean McClain, Mark Valasek
  • Anti-CDH6 antibody and method of producing an anti-CDH6 antibody-drug conjugate
    Patent number: 11446386
    Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: September 20, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko Saito, Tsuyoshi Hirata, Kensuke Nakamura
  • TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo
    Patent number: 11440960
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 13, 2022
    Assignee: KYMAB LIMITED
    Inventors: Joana de Abreu Carvalho, Rachael Jane Kimber, Jamie Ian Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Matthew John McCourt, Richard Charles Alfred Sainson, Mohammed Hanif Ali, E-Chiang Lee, Stephen Douglas Gillies
  • Method for treating a chronic itch condition by administering small molecule MrgprX4 antagonists
    Patent number: 11442059
    Abstract: The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 13, 2022
    Assignee: The Johns Hopkins University
    Inventors: Xinzhong Dong, Chirag Vasavda, Solomon H. Snyder, James Meixiong, Yingying Cheng, Nathachit Limjunyawong, Xintong Dong
  • Antibody inhibitors of IL-38 and methods of use thereof for treating or reducing the likelihood of cancer in a subject
    Patent number: 11427630
    Abstract: An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: August 30, 2022
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Andreas Weigert, Javier Mora, Bernhard Brüne, Mateusz Putyrski, Michael John Parnham, Andreas Ernst
  • Stable antibody variable domain framework combinations and methods of use thereof
    Patent number: 11421035
    Abstract: The present invention relates to novel antibody variable domain combinations with advantageous properties.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: August 23, 2022
    Assignee: Numab Therapeutics AG
    Inventors: Dania Diem, Christian Hess, Sebastian Meyer, David Urech
  • Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)
    Patent number: 11421036
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 23, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon, Allen Radin
  • Antibodies that bind to dengue virus serotype 4 (DENV4) and methods of making and using the same
    Patent number: 11407818
    Abstract: The present disclosure relates to polypeptides that specifically bind to Dengue virus non¬structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIH YS GGTN YNPS LKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: August 9, 2022
    Assignee: The United States of America, as Represented By The Secretary, Department of Health and Human Services
    Inventors: Elizabeth Anne Hunsperger, Tesfaye Gelanew Taye